Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib plus TACE as adjuvant therapy for HCC
NCT05161143Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Peking Union Medical College Hospital. Primary endpoint: 1 year Recurrence-Free Survival rate. Status: unknown.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05161143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161143.